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Background: There is increasing evidence that vitamin D deficiency is a risk factor for cancer, however it remains
uncertain whether vitamin D deficiency also predisposes to death from cancer. The aim of the study was to
determine the association between serum 25-hydroxy-vitamin D (25 (OH) D) concentrations and cancer-specific
mortality in a community-based cohort of older post-menopausal women.
Methods: Cox proportional regression analyses were conducted to examine the association between serum 25
(OH) D concentrations and the risk of overall and site-specific cancer mortality in a cohort of elderly women.
Results: Over a median follow-up time of 10 years, a total of 84 cancer deaths were observed. Women with lower
serum 25 (OH) D concentrations were at an increased risk of cancer death, but not for incident cancer. The excess
risk for cancer death was observed with serum 25 (OH) D concentration less than 64 nmol/L (the median value)
[adjusted HR: 1.61 (95% CI: 1.02 - 2.54, p = 0.04]. For every 30 nmol/L reduction in serum 25 (OH) D concentrations,
there was a 30% increase in the overall risk of cancer death [adjusted HR: 1.33; 95% CI: 1.03 – 1.72, p = 0.02]. The
excess risk appeared to be site-specific and greatest in those with haematological cancers [adjusted HR: 2.13: 95%
CI: 1.0 – 4.55, p = 0.05].
Conclusions: In elderly women, lower serum 25 (OH) D concentrations appear to be an independent risk factor for
cancer-specific mortality, but not a risk factor for the development of cancer.
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Vitamin D deficiency is increasingly recognised as an
important global public health problem. There is a grow-
ing body of epidemiological evidence demonstrating an
inverse relationship between lower serum 25-hydroxy-
vitamin D (25 (OH) D) concentrations and adverse health
outcomes in the general population [1,2]. Among post-
menopausal women with serum 25 (OH) D concentra-
tions less than 40 nmol/L, there was at least a two-fold
increased risk of all-cause and cardiovascular-related mor-
tality compared to women with 25 (OH) D concentrations
greater than 64 nmol/L [3,4]. Observational studies have
shown that lower serum levels of 25 (OH) D concentra-
tions may also be linked to several types of common can-
cers such as breast, prostate, colorectal and skin [3,5-9].* Correspondence: germaine.wong@health.nsw.gov.au
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unless otherwise stated.Two controlled trials have assessed the impact of vitamin
D supplementation and the incidence of cancer with con-
flicting results. The largest trial involved over 36,000
women randomized to combination calcium and vitamin
D supplementation and matching placebo and found no
significant effects on the incidence of cancer in post-
menopausal women after an average of 7 years of follow
up [10]. The other randomized controlled trial found a
significant reduction in overall cancer risk by 60% with
calcium and vitamin D supplementation in 1,179 healthy
post-menopausal women with high baseline serum 25
(OH) D concentrations over a follow-up period of 4 years
[11].
Observational studies have also produced conflicting re-
sults regarding the risk of cancer death and reduced serum
25 (OH) D concentrations. Several population-based cohort
studies have shown a linear association between lower serum
25 (OH) D concentrations and an increased risk of overall
cancer mortality [12-15], whilst another study reported no
increased risk of cancer death associated with vitamin DThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hort studies demonstrated a strong, inverse and independent
relationship between serum 25 (OH) D concentrations and
non-vascular mortality. After adjustment for measured con-
founders, cause-specific analyses showed that there was a
16% reduction in cancer mortality for every 2-fold increase
in baseline serum 25 (OH) D concentrations [17]. However,
a more recent systematic review of prospective epidemio-
logical studies has failed to demonstrate a consistent asso-
ciation between 25 (OH) D concentration and cancer
mortality in the general population [18]. Previous studies,
however, have not examined the threshold of serum 25
(OH) D concentrations that is associated with an in-
creased in site-specific cancer deaths in older women, nor
taken into consideration the competing risk of death when
examining cancer-specific mortality. In this study, we
aimed to determine the association between serum 25
(OH) D concentrations and cancer-specific mortality in a
community-based cohort of older women.
Methods
Study population
Data were obtained from a cohort of elderly women
recruited to a randomised controlled trial of oral cal-
cium supplements to prevent osteoporotic fractures,
the Calcium Intake Fracture Outcome Study (CAIFOS)
Australian Clinical Trials Registry Registration Number:
ACTRN012607000055404). Human ethics approval for
the use of linked data for the project was provided by the
Western Australian Department of Health Human Re-
search Ethics Committee (DOHWA HREC), project num-
ber #2009/24. Full details of the recruitment methods are
reported elsewhere [19]. In short, a total of 1500 women
were recruited in 1998 and randomised to receive either
1.2 g of elemental calcium in the form of calcium carbon-
ate or a matching placebo. Participants were followed over
10 years.
Baseline data were collected on self-reported medical and
treatment histories, and the associated major risk factors
such as smoking status and history of alcohol intake. Systolic
and diastolic blood pressures were recorded using a mercury
column manometer with an adult cuff after the participants
had been seated and resting for at least 5 minutes. Baseline
weight (using digital scales with participants wearing light
clothes and no shoes), height (assessed using a stadiometer)
and blood pressure (an average of 3 measurements) were ob-
tained at recruitment. Blood samples were also taken for cre-
atinine, albumin, calcium, phosphate, total cholesterol and
triglyceride. Prevalent chronic kidney disease was identified
using hospital records between 1980 and 1998.
Assessment of exposure
Serum 25 (OH) D2 and D3 concentrations were deter-
mined using a validated LC-MS/MS (Liquid ChromatographyTandem Mass Spectrometry) method at the RDDT La-
boratories (Bundoora, VIC, Australia). Between-run
coefficients of variation (CVs) were 10.1% at a 25
(OH) D2 mean concentration of 12 nmol/L and 11.3%
at a 25 (OH) D3 mean concentration of 60 nmol/L. Our
exposure factor, serum 25 (OH) D concentration, is the
combined serum 25 (OH) D2 and D3 concentrations.
Western Australia data linkage system
The Western Australia Data Linkage System (WADLS)
is a comprehensive, population-based linkage system
connecting 40 years of data from over thirty health re-
lated datasets for Western Australian residents coded
using International Classification of Diseases (ICD)
codes. The linkage system provides a complete validated
record of every participant’s primary diagnosis hospitali-
zations and up to twenty-one additional diagnosis hospi-
talizations codes and cause of death from the coded
records of the death certificates or from cancer registry.
Record linkage
The Human Ethics Committee of the University of
Western Australia approved the study and written in-
formed consent was obtained prior to recruitment. The
linkage process, using probabilistic linkage software, was
carried out at Data Linkage Western Australia. Using
key identifiers such as age, gender, addresses, post-codes
from the CAIFOS study cohort, the WADLS then cre-
ated a unique data linkage key to records of the same
person within the WADLS database and the process
would take multiple passes through datasets using differ-
ent arrangements of the data items at each pass.
Assessments of deaths
Cancer and non-cancer deaths were provided by the
WADLS as documented on the hospital death certifi-
cates and previous medical history, and the coded dis-
charge diagnosis data including all public and private
inpatient hospitalizations and deaths within Western
Australia using the ICD 9th and 10th and the revision
codes for malignancy (ICD-10-AM codes C15-26, C30-
39, C43-58, C64-75), atherosclerotic vascular disease: is-
chemic heart disease excluding arrhythmias (ICD-9-CM
codes 410–414 and ICD-10-AM codes I20-I25); heart
failure (ICD-9-CM code 428 and ICD-10-AM code I50);
cerebrovascular disease excluding hemorrhage (ICD-9-
CM codes 433–438 and ICD-10-AM codes I63-69,
G45.9) and peripheral arterial disease (ICD-9-CM codes
440–444 and ICD-10-AM codes I70-74).
Statistical analyses
Statistical analyses were performed using Stata 11 (Stata
Crop, 4905 Lakeway Drive College Station, Texas 77845,
USA) and SAS 9.3 (SAS Institute Inc, 100 SAS Campus
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tics of women with the different baseline serum 25 (OH)
D concentrations were compared using student’s t test
for means and chi-square for proportions (Table 1). The
follow-up periods in survival analyses were defined from
the time of first inclusion into the trial (from 1998
through 2008) to the time of death from cancer. People
alive or died from other causes were censored at the end
of the follow-up period (31st December 2008) or date of
death.
Cause-specific analyses for cancer death
The proportion of participants alive was calculated using the
Kaplan-Meier method. Univariate Cox regression models
were developed to assess the risk factors of cancer mortality





Age at entry (years, mean, sd) 75.1 (2.7)
Body mass index (kg/m2, mean, sd) 26.8 (4.5)
Systolic blood pressure (mmHg, mean, sd) 138.0 (18.1)
Diastolic blood pressure (mmHg, mean, sd) 73.4 (11.0)
Previous and current smokers (n, %) 219 (35.1)
Diabetes (n, %) 36 (6.0)
Chronic kidney disease (n, %) 43 (6.9)
Cardiovascular disease (n, %) 104 (16.7)
Daily alcohol use (grams, mean, sd) 6.1 (9.0)
Medication use (n, %)
Angiotension-converting enzyme inhibitors or




Treatment with calcium supplements (n, %) 314 (50.4)






Creatinine (umol/L, mean, sd) 79.8 (15.9)
Albumin (g/L, mean, sd) 44.0 (2.7)
Calcium (mmol/L, mean, sd) 2.35 (0.1)
Phosphate (mmol/L, mean, sd) 1.18 (0.1)
Estradiol 26.7 (14.6)
Estimated GFR (ml/min/1.73 m2, mean, sd) 64.9 (13.3)association with cancer death at P < 0.25 in the unadjusted
analyses were included in the multivariable-adjusted ana-
lyses. Using a step-wise backward elimination process, the
least significant variables were then removed from the base
model. Only variables with P < 0.05 remained in the final
parsimonious model. In all models, we adjusted for age, sea-
son, and smoking status. Potential effect modification was
also tested between the study factor (serum 25 (OH) D con-
centrations) and all other covariates using the two-way inter-
action term. There were no effect modifications between
serum 25 (OH) D concentration and other study factors.
The proportional hazard assumptions of all Cox regression
models were tested statistically and graphically by plotting
the Schoenfield residuals. Site specific analyses were also
performed to assess the relationship between reduced serum
25 (OH) D concentrations and the risk of the six mosttamin D concentration (nmol/L) P values for
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The serum 25 (OH) D concentrations were modelled as a
continuous and categorical variable (less than and greater or
equal than the median serum 25 (OH) D concentrations
[<64 nmol/L or ≥ 64 nmol/L]). We also used fractional poly-
nomials in the Cox regression model to evaluate the func-
tional form of the association between the continuous
variable of serum 25 (OH) D concentrations and overall
cancer mortality. The hazard ratio for the difference be-
tween the serum 25 (OH) D concentrations and the median
value of 64 nmol/L was estimated from the model coeffi-
cient and plotted to show the change in the risk of cancer
death with lower and higher serum 25 (OH) D concentra-
tions from the median value.
Cause-specific analyses for cancer incidence
To determine whether the higher risk of cancer mortal-
ity was a reflection of the underlying cancer risk among
those with reduced serum 25 (OH) D concentrations,
we also assessed the association between overall cancer
incidence and serum 25 (OH) D concentrations in the
adjusted Cox regression model.
Competing risk analyses
As a secondary analysis, we conducted a nonparametric
estimation of the cumulative incidence of cancer mortal-
ity in participants with varying baseline serum 25 (OH)
D concentrations, taking into account the informative
nature of censoring due to competing risk. The cumula-
tive incidence of cancer death is estimated using two
main steps. We first considered the event of interests
(i.e. cancer death) and other competing events such as
vascular death as ‘events” and then calculated the Kaplan-
Meier estimate of the overall “events”. Anyone who was
not experiencing the “event” (i.e. event free) was consid-
ered censored [20].
Sensitivity analyses
To ensure that all cancer diagnoses and subsequent
deaths occurred before measurements of serum 25 (OH)
D concentrations were taken, we had excluded partici-
pants who died from cancer within the first two years
since the inception of the study in our sensitivity ana-
lyses. We also assessed the risk of cancer mortality
among those with lower serum concentrations of 25
(OH) D (less than 46 nmol/L) compared to those with
the highest quartile of serum 25 (OH) D concentrations
(≥83 nmol/L).
Results
From a total of 1500 participants, 228 (15.2%) with in-
complete serum 25 (OH) D concentration and a further
84 participants (5.6%) with cancers diagnosed prior to
inception of the study were excluded, leaving a total of1188 participants in the final analyses. The median age,
body mass index (BMI), and baseline serum 25 (OH) D
concentrations of those included in the study were 75.1
(Interquartile range (IQR): 73 to 77) years, 26.5 (IQR:
23.8 to 29.7) kg/m2 and 64 (IQR: 46.2 to 83.2) nmol/L,
respectively. The median follow-up period was 10 years
(interquartile range: 0.41 years), resulting in 12,647
persons-years of follow-up.Baseline characteristics of the study participants
The baseline characteristics are shown in Table 1. A total of
591 (49.7%) participants had serum 25 (OH) D concentra-
tions less than 64 nmol/L. Compared to those with serum
25 (OH) D concentrations above or equal to the median
(≥64 nmol/L), participants with serum 25 (OH) D concen-
trations less than 64 nmol/L had lower BMI (p = 0.02),
lower serum albumin (p = 0.004), calcium (p = 0.005), and a
higher estimated glomerular filtration rate (p = 0.001) at
baseline.Frequency and incidence of cancer death
A total of 274 deaths were observed during the follow-
up period, with 84 (30.7%) and 124 (45.3%) cancer and
vascular deaths, respectively. Cancers of the digestive
system (27, 32.1) were the most common cause of can-
cer death, followed by lung (13, 15.4%), haematological
(11, 13.0%), breast (6, 7.1%), and cancers of the central
nervous system (5, 6.0%).Association between serum 25 (OH) D concentrations and
cancer-mortality
Table 2 shows the unadjusted and adjusted risk factors
for cancer mortality. A significant increase in cancer
mortality was observed in those with reduced levels of
serum 25 (OH) D concentrations. Figure 1 shows how
the adjusted hazard ratio (HR) for incident cancer death
changes as the continuous measures of serum 25 (OH)
D concentrations move further away from the median
value of 64 nmol/L (which has an HR of 1). For every
30 nmol/L reduction in serum 25 (OH) D concentra-
tions, there was a significant increase in cancer-specific
mortality by 33% from a threshold of 64 nmol/L, after
adjusting for the effects of age, seasonal changes, chronic
kidney disease and smoking status (adjusted HR: 1.33;
95% confidence interval (CI): 1.03 – 1.72, p = 0.02).
Compared to participants with serum 25 (OH) D con-
centrations greater than or equal to 64 nmol/L, the ad-
justed HR for cancer death among those with serum 25
(OH) D concentrations less than 64 nmol/L was 1.61
(95% CI: 1.02 - 2.54, p = 0.04). We have also shown that
the best-fit fractional polynomial was linear in the adjusted
model (Additional file 1).
Table 2 Risk factors for cancer mortality
Variables Unadjusted
HR
95% CI P-values Adjusted HR 95% CI p-values
Patient characteristics
Age (per SD increase) 1.05 0.86 – 1.28 0.64 1.02 0.84 – 1.25 0.83
Diastolic blood pressure (per 10 mmHg increase) 1.10 0.90 – 1.34 0.35 - - -
Systolic blood pressures (per 10 mmHg increase) 0.97 0.87 – 1.09 0.60 - - -
Previous and current smoker 1.45 0.97 – 2.17 0.07 1.80 1.17 – 2.77 0.008
Body mass index (per SD increase) 0.99 0.81 – 1.21 0.93 - - -
Daily alcohol use (per gram increase) 1.09 0.85 – 1.41 0.49 - - -
Co-morbidities
Diabetes 1.32 0.61 – 2.86 0.48 - - -
Chronic kidney disease 2.37 1.27 – 4.50 0.007 2.43 1.28 – 4.62 0.007
Cardiovascular disease 1.30 0.74 – 2.27 0.36 - - -
Season at recruitment
Spring Ref - 0.39 Ref - -
Summer 2.07 0.63 – 6.78 1.02 0.24 – 4.34 0.97
Autumn 1.48 0.87 – 2.54 1.71 0.99 – 3.00 0.06
Winter 1.17 0.70 – 1.96 1.27 0.75 – 2.14 0.37
Treatment allocation
Calcium supplements 1.11 0.76 – 1.63 0.59 1.09 0.73 – 1.62 0.67
Laboratory measurements
25 (OH) Vit D (nmol/L)
>83 Ref - 0.06 Ref - 0.04
>64 - 83 1.95 1.02 – 3.74 2.23 1.09 – 4.58
>46 - 64 2.27 1.21 – 4.27 2.55 1.24 – 5.26
0 - 46 2.12 1.11 – 4.05 2.63 1.26 – 5.45
Albumin (per SD increase) 0.95 0.79 – 1.13 0.53 - - -
Calcium (per SD increase) 1.01 0.83 – 1.22 0.93 - - -
Phosphate (per SD increase) 0.70 0.14 – 3.46 0.66 - - -
Estimated GFR (per SD increase) 1.03 0.84 – 1.27 0.78 - - -
Figure 1 Adjusted HR across continuous measures of serum 25
(OH) D concentrations.
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competing risk of death
Figure 2 shows the adjusted cumulative incidence of
cancer mortality and the serum 25 (OH) D concentra-
tions (dichotomized below and/or above the group me-
dian value of 64 nmol/L) after adjusting for competing
vascular deaths, age, smoking status, systolic and dia-
stolic blood pressures. The cumulative incidence of can-
cer mortality among participants with 25 (OH) D
concentrations < 64 nmol/L and ≥ 64 nmol/L 10 years after
inception of the study were 0.096 and 0.062, respectively
(p = 0.02).
Site-specific risk of cancer death
Figure 3 shows the selected site-specific HR for cancer
death for every 30 nmol/L increase in serum 25 (OH) D
concentrations. There was a significant association
Figure 2 Adjusted cumulative incidence of cancer mortality by serum 25 (OH) D concentrations.
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increased risk of death from haematological cancers after
adjusting for the effects of age, smoking status, seasonal
changes and chronic kidney disease (adjusted HR: 2.13;
95% CI: 1.0 – 4.55, p = 0.05). This association was not
significant in other cancer types including digestive,
lung, breast, female genital and cancers of the central
nervous systems.Figure 3 Serum 25 (OH) D concentrations and site-specific cancer moSensitivity analyses
We also analyzed the cancer mortality risk comparing
those with very low serum 25 (OH) D concentrations
(less than 46 nmol/L) to those with baseline serum 25
(OH) D concentrations ≥ 83 nmol/L and found an in-
creased risk of cancer death by at least 2.6-fold among
those with very low serum 25 (OH) D concentrations
(adjusted HR: 2.63; 95%CI: 1.26 – 5.45, p = 0.04). Inrtality.
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with serum 25 (OH) D concentration below the median
(less than 64 nmol/L) remained significant after exclud-
ing participants who died from cancer within the first
two years since inception of the study (adjusted HR:
1.59; 95% CI: 1.03 – 2.44, p = 0.04).
Association between serum 25 (OH) D concentrations and
cancer incidence
A total of 191 incident cancers were observed during the
follow-up period. The cumulative incidence of cancer
among participants with serum 25 (OH) D concentra-
tions < 64 nmol/L and ≥ 64 nmol/L ten years after incep-
tion of the study were 0.19 and 0.18, respectively
(p = 0.60) (Figure 4). After adjusting for measured con-
founders, cancer risk was not significantly increased
among those with serum 25 (OH) D concentrations
below the median value (adjusted HR: 0.89, 95%CI: 0.67
– 1.18, p = 0.41, for those with 25 (OH) D levels less
than 64 nmol/L).
Discussion
In this large study of Australian women, with over 12,000
person-years of follow-up, we have shown that women
with lower baseline were at an increased risk of overall
cancer death but not for incident cancer. For every
30 nmol/L reduction in serum 25 (OH) D concentrations,
there was an increased risk of cancer specific mortality by
at least 30%, after adjusting for the effects of age, seasonal
changes, smoking status and chronic kidney disease. The
increased risk of cancer death also appeared to be site-
specific, with the greatest risk of death from haemato-
logical malignancies observed among women with lower
serum 25 (OH) D concentrations.
To our knowledge, this is a large population-based cohort
study with the longest follow-up time to date investigating
the association between serum 25 (OH) D concentrations
and the overall and site-specific risk of cancer mortality inFigure 4 Cumulative incidence of cancer by serum 25 (OH)
D concentrations.elderly women. Low serum 25 (OH) D concentrations have
been shown to be associated with adverse clinical outcomes
among those suffering from cancers. Previous ecological
studies have reported breast cancer mortality was highest for
cancer diagnosed in winter, the seasons with the highest
serum 25 (OH) D concentrations [21]. Lower serum 25
(OH) D concentrations have also been associated with more
advanced stages of breast cancers. More recently, a prospect-
ive cohort study of over 1300 older women suffering from
breast cancer has shown that lower serum 25 (OH) D con-
centrations were linearly associated with 10% increased risk
of cancer-related mortality and a 15% increased risk of dis-
ease recurrence for every 10 nmol/L decrement in serum 25
(OH) D concentrations [22].
Previous studies that have investigated the association
between cancer mortality and serum 25 (OH) D concen-
trations have observed conflicting results. Several
population-based cohort studies have reported an associ-
ation between higher serum 25 (OH) D concentrations
and reduction in overall cancer mortality [15,23,24]. In
particular, significant inverse associations were observed
for colorectal, pancreatic, oral and esophageal cancer
mortality [12,25]. In contrast, results from the National
Health and Nutrition Examination Survey (NHANES)
study of over 16,000 participants, have shown no signifi-
cant associations between serum 25 (OH) D concentra-
tions and overall cancer mortality after adjustments for
age, gender, smoking and ethnicity [16].
A significant association between haematological ma-
lignancies was detected among those with reduced
serum 25 (OH) D concentrations. Although the exact
biological rationale for the protective effects of vitamin
D is unclear, findings from animal studies have shown
that vitamin D can stimulate the production of a known
antagonist of c-myc, a protein critical in promoting cell
proliferation and the transformation of pre-malignant to
malignant cells [26]. In addition, in vitro studies have
also shown that the active metabolite of Vitamin D, 1,25
(OH) 2D, can inhibit the proliferation, angiogenesis and
metastatic potential of tumour cells thereby suggesting a
critical role of vitamin D in the control of cancer cell
growth [27]. Studies have also reported a poorer progno-
sis among those with hypovitaminosis D in a cohort of
patients with chronic lymphocytic leukaemia. The over-
all hazard for death is at least 1.6 times greater among
patients with serum 25 (OH) D concentrations less than
25 ng/ml. In vitro studies have shown that treatment
with Vitamin D analogues induces apoptosis of the mito-
chondrial pathway, therefore leading to inhibition of the
proliferation of the B and T lymphocytes and lymphoma
cell lines.
The higher serum 25 (OH) D concentration thresh-
olds that predicted the increased risk of cancer mortality in
our study cohort is unexpected. Most published literature
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with the increased risk of overall and site-specific cancer
death [28]. The higher than predicted threshold for the in-
creased risk of cancer mortality may be due to chance or po-
tential measurement errors such as regression dilution
errors. Random measurement error in the exposure variable
may potentially attenuate the association between vitamin D
concentrations and cancer mortality at the pre-specified
thresholds. This occurs because the measurements often
fluctuate unpredictably around the true values, due to bio-
logical variations or imprecision of the measurement tool it-
self. The exposure factor, serum 25 (OH) D concentrations
in our study, were measured only once at baseline, rather
than repeatedly to minimize the potential errors. Our find-
ings suggest future trials may consider higher doses of
vitamin D to achieve a target serum 25 (OH) D concentra-
tion of 60 nmol/L or greater when evaluating the benefits
and harms of vitamin D supplementation in older women
with cancers.
Our study has a number of strengths. It is population-
based, with very little missing baseline data, and over 12,
647 person years of follow up. Detailed data on con-
founders were also available. Using linked data from a
mandatory state-wide cancer registry, we have accurately
ascertained all cancer deaths since inception of the
cohort.
Our study has a number of potential limitations. We
excluded 17.1% of the original sample because of incom-
plete serum 25 (OH) vitamin D concentrations, but the
number is relatively small, and those excluded have simi-
lar characteristics to those in the overall study popula-
tion. The progressive change in serum 25 (OH) D
concentrations over time and the risk of cancer death
was not evaluated because only baseline serum 25 (OH)
D concentrations were available. Findings from our
study may not be generalisable to other populations such
as the African Americans and Indigenous Australians
because all participants are white post-menopausal
Australian women. The lack of association between
site-specific cancer mortality and serum 25 (OH) D con-
centrations may be due to the limited number of events
for individual site-specific cancers, and therefore insuffi-
cient power to detect any significant differences in the risk
of cancer deaths among women with lower and higher
serum 25 (OH) D concentrations. Finally, although we
had fully adjusted for all known risk factors for cancer
death available in the dataset, residual confounding by
other unmeasured socioeconomic and epidemiological
factors such as physical activity and ultraviolet exposure
may be present.
Conclusions
In conclusion, lower baseline serum 25 (OH) D concen-
trations were independently associated with an increasedrisk of overall cancer mortality. However, the threshold
of serum 25 (OH) D concentrations associated with the
increased risk of cancer mortality may vary according to
the characteristics of the study population. Additional
prospective studies are required to investigate the associ-
ation between serum 25 (OH) D concentrations and
site-specific and overall incidence and mortality in older
populations of both genders. Future carefully designed
randomised controlled trials of vitamin D supplementa-
tion in older adults with cancers may be warranted to
determine whether this association is causal and poten-
tially reversible.
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